Horseshoe Crab Sustainability.pdf

Current horseshoe crab harvesting practices cannot support global demand for Tachypleus and Limulus Amoebocyte Lysate (TAL/LAL), used in the pharmaceutical and medical device industries for endotoxin detection. The demand for TAL/LAL is increasing due to the growth of the global healthcare industry, but the horseshoe crab population is declining due to over-harvesting, habitat loss, and other threats.

The pharmaceutical and medical device industries rely heavily on TAL/LAL for quality control, with approximately 25% of the medical device market dependent on it. The vaccine market, which is a small but rapidly growing segment of the pharmaceutical industry, is also heavily reliant on endotoxin detection.

The World Health Organization (WHO) projects a 10-15% annual growth in the vaccine market over the next 15 years, compared to 5-7% for pharmaceuticals. The veterinary vaccine market is also growing rapidly.

To ensure the long-term availability of TAL/LAL, the pharmaceutical and medical device industries must adopt sustainable practices, such as reducing animal-based testing, promoting conservation of horseshoe crab species, and developing alternative testing methods. The industries can work with conservation organizations and governments to implement best practices for TAL/LAL production, reduce waste, and protect horseshoe crab habitats.

Key statistics:

8-15% mortality rate for horseshoe crabs due to LAL production
100% mortality rate for horseshoe crabs due to TAL production
25% of the medical device market dependent on TAL/LAL
10-15% annual growth projected for the vaccine market
5-7% annual growth projected for the pharmaceutical market

Key recommendations:

Reduce animal-based testing
Promote conservation of horseshoe crab species
Develop alternative testing methods
Implement best practices for TAL/LAL production
Protect horseshoe crab habitats
* Support conservation organizations and governments in their efforts to protect horseshoe crab species.